Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
WHWK
STRONG SELLWhitehawk Therapeutics, Inc. · Healthcare · United States · $236M
COMPANY DESCRIPTION
Whitehawk Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies and targeted treatments for oncology and inflammatory diseases. The company's competitive position is driven by its proprietary drug discovery platform and intellectual property surrounding specific cellular pathways. It operates as a high-risk, research-driven biotechnology firm seeking strategic partnerships for clinical development.
Insufficient price history for this range.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of WHWK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| WHWK | Whitehawk Therapeutics, Inc.(you) | $236M | 9 | STRONG SELL |
| ARMP | Armata Pharmaceuticals, Inc. | $254M | 12 | STRONG SELL |
| FHTX | Foghorn Therapeutics Inc. | $248M | 6 | STRONG SELL |
| FULC | Fulcrum Therapeutics, Inc. | $255M | 12 | STRONG SELL |
| CAMP | CAMP4 THERAPEUTICS CORPORATION | $210M | 12 | STRONG SELL |
| ALEC | Alector, Inc. | $192M | 10 | STRONG SELL |
| IVVD | Invivyd, Inc. | $280M | 8 | STRONG SELL |
| TRDA | Entrada Therapeutics, Inc. | $278M | 12 | STRONG SELL |
| AVXL | Anavex Life Sciences Corp. | $250M | 5 | STRONG SELL |
| KRRO | Korro Bio, Inc. | $190M | 11 | STRONG SELL |
Peer medians: ROE -22.3% · P/E 25.1x · Gross margin 44.3%